The company makes regenerative medical products to harvest bone marrow to help bone healing. One product is plant based and does not need surgery to use. You can read the information below that describes the product lines they offer all relative to bone regeneration. BD
Orthovita is an orthobiologics and biosurgery company that develops and markets innovative medical implants. Our orthobiologics platform offers products for the fusion, regeneration and fracture fixation of human bone, while our biosurgery platform currently offers products for controlling intra-operative bleeding, also known as hemostasis.
Our current fusion and regeneration products are based on our proprietary, market-leading Vitoss™ Bone Graft Substitute technology which addresses the non-structural bone grafting market with synthetic, bioactive alternatives to patient- and cadaver-derived bone tissue. Cortoss™ Bone Augmentation Material, an injectable polymer composite that mimics the structural characteristics of human bone, provides the basis for our fracture fixation portfolio. Cortoss Bone Augmentation Material is cleared in the U.S. for treatment of vertebral compression fractures. Our hemostasis portfolio includes Vitagel™ Surgical Hemostat, a unique, collagen-based matrix that controls bleeding and facilitates healing, and Vitasure™ Absorbable Hemostat, a plant-based product that can be deployed quickly throughout surgery.
Stryker said on Monday that it will pay $3.85 a share for Orthovita, a 41 percent premium over the company's closing share price on Friday. The value of the transaction includes net debt of $12 million.
Orthovita competes in the $5 billion market for orthobiologics, which are proteins and other agents designed to boost the body's healing process. It is a leader in synthetic bone grafts.
The deal should help Stryker better compete against larger rivals Medtronic Inc (MDT.N) and Johnson & Johnson (JNJ.N), while Stryker's marketing heft should bolster sales of Orthovita's product lines, analysts said.